glp 1 and sarcopenia in the Era of GLP-1 Medications Emerging Role of Myostatin Inhibitors Targeting Sarcopenia in CKD: The

This activity can help reduce feelings of hunger while activating another group of neurons involved in regulating food intake

Many gastroprotective agents lose effectiveness over weeks

Microdosing and Long-Term Use Microdosing GLP-1 medications is an emerging practice that allows patients to use the least amount of medication necessary to achieve the desired effects

Monotherapy-Dr Prabhat Ranjan The combination therapy of metformin and GLP-1 receptor agonists (GLP-1 RAs) demonstrates superior safety over monotherapy, while revealing novel adverse events and demographic-specific risk patterns, a large-scale pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) has reported